JP2014528446A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528446A5
JP2014528446A5 JP2014534619A JP2014534619A JP2014528446A5 JP 2014528446 A5 JP2014528446 A5 JP 2014528446A5 JP 2014534619 A JP2014534619 A JP 2014534619A JP 2014534619 A JP2014534619 A JP 2014534619A JP 2014528446 A5 JP2014528446 A5 JP 2014528446A5
Authority
JP
Japan
Prior art keywords
methyl
benzo
azetidin
imidazole
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014534619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/058220 external-priority patent/WO2013052395A1/en
Publication of JP2014528446A publication Critical patent/JP2014528446A/ja
Publication of JP2014528446A5 publication Critical patent/JP2014528446A5/ja
Withdrawn legal-status Critical Current

Links

JP2014534619A 2011-10-06 2012-10-01 1,3−置換アゼチジンpde10阻害剤 Withdrawn JP2014528446A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544065P 2011-10-06 2011-10-06
US61/544,065 2011-10-06
PCT/US2012/058220 WO2013052395A1 (en) 2011-10-06 2012-10-01 1,3-substituted azetidine pde10 inhibitors

Publications (2)

Publication Number Publication Date
JP2014528446A JP2014528446A (ja) 2014-10-27
JP2014528446A5 true JP2014528446A5 (enExample) 2015-11-19

Family

ID=48044097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534619A Withdrawn JP2014528446A (ja) 2011-10-06 2012-10-01 1,3−置換アゼチジンpde10阻害剤

Country Status (8)

Country Link
US (1) US9365562B2 (enExample)
EP (1) EP2763672B1 (enExample)
JP (1) JP2014528446A (enExample)
AR (1) AR088258A1 (enExample)
AU (1) AU2012318874A1 (enExample)
CA (1) CA2851082A1 (enExample)
TW (1) TW201321369A (enExample)
WO (1) WO2013052395A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2919781B1 (en) * 2012-11-15 2017-06-28 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles as pde10 inhibitors
TW201422610A (zh) * 2012-11-15 2014-06-16 Merck Sharp & Dohme 作爲pde10抑制劑之經二級醇取代之三唑
WO2014078217A1 (en) * 2012-11-15 2014-05-22 Merck Sharp & Dohme Corp. Cyclopropyl imidazopyridine pde10 inhibitors
EP2922823B1 (en) 2012-11-20 2018-10-31 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
US9273033B2 (en) 2012-11-20 2016-03-01 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as PDE10 inhibitors
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
FR3040057A1 (fr) * 2015-08-13 2017-02-17 Inventiva Composes de type azetidine carboxylique
US10583269B2 (en) 2016-06-01 2020-03-10 Becton, Dickinson And Company Magnetized catheters, devices, uses and methods of using magnetized catheters
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
US20230135152A1 (en) * 2020-02-11 2023-05-04 AcuraStem Incorporated Pikfyve kinase inhibitors
WO2025049402A1 (en) * 2023-08-28 2025-03-06 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1100777C (zh) * 1997-02-19 2003-02-05 伯莱克斯实验室公司 作为nos抑制剂的n-杂环衍生物
WO2003087064A1 (en) 2002-04-18 2003-10-23 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
RS20050532A (sr) * 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
US20080161278A1 (en) 2005-03-23 2008-07-03 Astrazeneca Ab 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
JP2008540443A (ja) 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン
WO2007143823A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
MX347085B (es) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
CA2709203A1 (en) 2007-12-13 2009-06-18 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
WO2009120094A2 (en) * 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
CA2800578A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
EP2621276B1 (en) 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
CA2845578C (en) 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors

Similar Documents

Publication Publication Date Title
JP2016512259A5 (enExample)
CA2592986C (en) Heteroaromatic quinoline compounds
JP2014521711A5 (enExample)
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
JP2014531465A5 (enExample)
US20130018039A1 (en) Imidazolyl-imidazoles as kinase inhibitors
ME02416B (me) Trpv4 antagonisтi
AU2012318874A1 (en) 1,3-substituted azetidine PDE10 inhibitors
JP2014518214A5 (enExample)
JP2017533946A5 (enExample)
JP2018522046A5 (enExample)
CA2351725A1 (en) Substituted pyrazoles as p38 kinase inhibitors
SI2763982T1 (en) Substituted benzylindazoles for use as inhibitors of Bub kinase in the treatment of hyperproliferative diseases
US20170173026A1 (en) Aminoquinazoline and pyridopyrimidine derivatives
EP1979343A2 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
JP2017500364A5 (enExample)
CA2899904A1 (en) Flap modulators
HRP20200440T1 (hr) 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori
US10894784B2 (en) Heteroarylbenzimidazole compounds
JP2016514717A5 (enExample)
JP2016522231A5 (enExample)
JP2020523309A5 (enExample)
JP2020529419A5 (enExample)
KR20110006662A (ko) 5-하이드록시피리미딘-4-카르복사미드 화합물
CN114502537A (zh) 突变型idh2抑制剂及其应用